We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Avances en el tratamiento del glioblastoma multiforme.
- Authors
JARAMILLO, SONIA; OSORIO, WALTER; ESPITIA, JUAN CARLOS
- Abstract
Glioblastoma multiforme is the most common central nervous system (CNS) primary tumor in men. Its incidence in Europe lies between 3 to 4 cases per 100,000 inhabitants and it represents 25% of all the CNS tumors and 50% of the primary tumors. Less than 3% of all patients diagnosed with glioblastoma multiforme survive more than 4 years and the average survival is of 6 months. Studies aiming to increase the survival rate, as well as to achieve longer asymptomatic periods are being carried out at present. The main goal of this review is to offer a brief recount on the progress in the treatment of glioblastoma multiforme, focusing on genetic therapy. The consulted literature showed, that there are only two types of mutations capable of defining the prognosis of this disease at this point; one is the presence of O6-methylguanine-DNA methyltransferase protein expression (MGMT) and the 1p/ 19q deletion on which we will emphasize in the course of this document.
- Subjects
EUROPE; NERVOUS system; CANCER in men; TUMORS; GLIOBLASTOMA multiforme; THERAPEUTICS
- Publication
Universitas Médica, 2010, Vol 51, Issue 2, p186
- ISSN
0041-9095
- Publication type
Article
- DOI
10.11144/javeriana.umed51-2.atgm